Dapagliflozin Early Benefit Explored in Reduced-EF Heart Failure Dapagliflozin Early Benefit Explored in Reduced-EF Heart Failure

Why have SGLT2-inhibitor clinical benefits in HFrEF trials been evident so soon after the drugs are started? Recent studies shed light on one potential mechanism among what are probably many.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news